These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30869180)

  • 1. Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation.
    Lerchen HG; Stelte-Ludwig B; Berndt S; Sommer A; Dietz L; Rebstock AS; Johannes S; Marx L; Jörißen H; Mahlert C; Greven S
    Chemistry; 2019 Jun; 25(35):8208-8213. PubMed ID: 30869180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads.
    Lerchen HG; Stelte-Ludwig B; Sommer A; Berndt S; Rebstock AS; Johannes S; Mahlert C; Greven S; Dietz L; Jörißen H
    Bioconjug Chem; 2020 Aug; 31(8):1893-1898. PubMed ID: 32667786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain.
    Stern L; Perry R; Ofek P; Many A; Shabat D; Satchi-Fainaro R
    Bioconjug Chem; 2009 Mar; 20(3):500-10. PubMed ID: 19196156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
    Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C
    Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers.
    Gray ME; Zielinski KM; Xu F; Elder KK; McKay SJ; Ojo VT; Benjamin SR; Yaseen AA; Brooks TA; Tumey LN
    Xenobiotica; 2024 Aug; 54(8):458-468. PubMed ID: 38738708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
    Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
    Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.
    Zhang M; Jiang Z; Chen S; Wu Z; Chen K; Wu Y
    Chem Biol Drug Des; 2018 Feb; 91(2):534-544. PubMed ID: 28994241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties.
    Sommer A; Berndt S; Lerchen HG; Forveille S; Sauvat A; Mumberg D; Kroemer G; Kepp O
    Oncoimmunology; 2022; 11(1):2037216. PubMed ID: 35154909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting.
    Ye J; Shin MC; Liang Q; He H; Yang VC
    J Control Release; 2015 May; 205():58-69. PubMed ID: 25483423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.
    Miller JT; Vitro CN; Fang S; Benjamin SR; Tumey LN
    Bioconjug Chem; 2021 Apr; 32(4):842-858. PubMed ID: 33788548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.
    Sutherland MS; Sanderson RJ; Gordon KA; Andreyka J; Cerveny CG; Yu C; Lewis TS; Meyer DL; Zabinski RF; Doronina SO; Senter PD; Law CL; Wahl AF
    J Biol Chem; 2006 Apr; 281(15):10540-7. PubMed ID: 16484228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.
    Seaman S; Zhu Z; Saha S; Zhang XM; Yang MY; Hilton MB; Morris K; Szot C; Morris H; Swing DA; Tessarollo L; Smith SW; Degrado S; Borkin D; Jain N; Scheiermann J; Feng Y; Wang Y; Li J; Welsch D; DeCrescenzo G; Chaudhary A; Zudaire E; Klarmann KD; Keller JR; Dimitrov DS; St Croix B
    Cancer Cell; 2017 Apr; 31(4):501-515.e8. PubMed ID: 28399408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates.
    Pei Z; Chen C; Chen J; Cruz-Chuh JD; Delarosa R; Deng Y; Fourie-O'Donohue A; Figueroa I; Guo J; Jin W; Khojasteh SC; Kozak KR; Latifi B; Lee J; Li G; Lin E; Liu L; Lu J; Martin S; Ng C; Nguyen T; Ohri R; Lewis Phillips G; Pillow TH; Rowntree RK; Stagg NJ; Stokoe D; Ulufatu S; Verma VA; Wai J; Wang J; Xu K; Xu Z; Yao H; Yu SF; Zhang D; Dragovich PS
    Mol Pharm; 2018 Sep; 15(9):3979-3996. PubMed ID: 30040421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of a novel prodrug, a S-trityl-
    Fukai R; Ogo N; Ichida T; Yamane M; Sawada JI; Miyoshi N; Murakami H; Asai A
    Eur J Med Chem; 2021 Apr; 215():113288. PubMed ID: 33640763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.
    Liu Y; Bajjuri KM; Liu C; Sinha SC
    Mol Pharm; 2012 Jan; 9(1):168-75. PubMed ID: 22044266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1.
    Lai J; Wang Y; Wu SS; Ding D; Sun ZY; Zhang Y; Zhou J; Zhou Z; Xu YC; Pan LQ; Chen SQ
    Biomaterials; 2018 Sep; 178():158-169. PubMed ID: 29933102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers.
    Liang Y; Li S; Wang X; Zhang Y; Sun Y; Wang Y; Wang X; He B; Dai W; Zhang H; Wang X; Zhang Q
    J Control Release; 2018 Apr; 275():129-141. PubMed ID: 29408580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.